📋 Table of Contents
- Why China Leads the World in CRISPR Clinical Trials
- CRISPR and Gene Therapy 101
- China's Regulatory and Clinical Advantage
- 2016 Milestone: The First-in-Human CRISPR Cancer Trial
- 2026 Milestone: UniXell UX-DA003 Dual FDA + NMPA Clearance
- Active Therapy Areas: Cancer, Blood Disorders, Genetic Disease, Infectious Disease
- Top Hospitals and Research Centers
- International Patient Access: Trial Enrollment
- Frequently Asked Questions
💡 Key Insight: China hosts the largest number of CRISPR clinical trials in the world, with active programs in oncology, blood disorders, inherited genetic diseases, and infectious disease. The 2016 first-in-human CRISPR cancer trial at West China Hospital opened the global era of in-human gene editing, and the June 2026 dual FDA + NMPA clearance of UniXell UX-DA003 confirmed that Chinese gene-editing platforms can meet the highest international regulatory bar.
Average gene therapy cost in China: $80,000-200,000 USD for ex vivo edited cell therapies
Average gene therapy cost in USA: $300,000-700,000+ USD (often $1M+ for some approved products)
Key selling point for international patients: Access to gene therapies that are not yet available in their home country, at 50-70% lower cost
🧪 CRISPR and Gene Therapy 101
Gene therapy is the use of genetic material — DNA or RNA — to treat or prevent disease. It includes a wide range of approaches: replacing a defective gene, inactivating a harmful gene, or introducing a new gene that helps the body fight disease.
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is the dominant gene-editing tool of the 2020s. It is essentially a programmable pair of "molecular scissors" — a guide RNA directs the CRISPR protein (commonly Cas9) to a specific DNA sequence, where the protein makes a precise cut. Scientists can use that cut to disable a gene, repair a mutation, or insert a new sequence. The 2020 Nobel Prize in Chemistry was awarded to Jennifer Doudna and Emmanuelle Charpentier for developing CRISPR.
The two main delivery models are:
- Ex vivo gene editing: Cells are removed from the patient, edited in a lab, expanded, and infused back. The most common example is CAR-T cell therapy, where T cells are engineered to recognize a patient's cancer.
- In vivo gene editing: The editing machinery is delivered directly into the body, typically via a viral vector (e.g., AAV) or lipid nanoparticle. Examples include in vivo gene editing for inherited retinal disease, hemophilia, and metabolic disorders.
China has built world-leading capability in both models — but the ex vivo CAR-T and stem cell-editing approach is where the country's clinical volume is most concentrated, building directly on the cancer hospital infrastructure described in our top cancer hospitals guide and CAR-T therapy hospitals article.
🏛️ China's Regulatory and Clinical Advantage
Three factors combine to give China the world's deepest CRISPR trial pipeline:
1. A More Streamlined Regulatory Path
The NMPA has historically permitted a wider range of gene-editing therapies to enter registered clinical trials than the US FDA or EU EMA. The IND-to-trial timeline is shorter, and the pathway for cell and gene therapies has been progressively clarified since 2017. For indications where no approved therapy exists, this regulatory accessibility is the difference between a near-term clinical option and no option at all.
2. Unmatched Patient Volume and Hospital Capacity
China's tertiary cancer centers and academic hospitals have patient volumes that can be 5-10x their Western counterparts. For a clinical trial, that means faster enrollment, more diverse patient profiles, and shorter time-to-readout. For an international patient, it means more open trials, more sites to choose from, and shorter wait lists.
3. A Mature Cell and Gene Therapy Manufacturing Ecosystem
Chinese GMP manufacturers produce viral vectors, lipid nanoparticles, and cell therapy products at significantly lower cost than US or EU CDMOs, while meeting comparable quality standards. The result: trial sponsors can run larger, more complex programs at lower per-patient cost — and that cost advantage is passed along to patients paying out of pocket for approved therapies.
🏆 2016 Milestone: The First-in-Human CRISPR Cancer Trial
China's leadership in CRISPR medicine began in 2016 with the first-in-human CRISPR clinical trial, conducted at West China Hospital, Sichuan University. In that trial, autologous T cells were extracted from patients with metastatic non-small cell lung cancer, edited ex vivo using CRISPR-Cas9 to knock out the PD-1 gene (a key immune checkpoint), expanded, and reinfused back into the patients. The trial demonstrated the safety of ex vivo CRISPR editing in humans and opened the global era of in-human gene editing medicine.
That single 2016 trial seeded a generation of follow-on programs — both in China and abroad. West China Hospital remains a top trial site for gene-editing oncology, and Chinese biopharma has grown into the largest single national pipeline of CRISPR-based therapies. For a deeper dive into the broader Chinese cancer clinical trial landscape, see our cancer treatment in China 2026 guide and the cost breakdown.
🏆 2026 Milestone: UniXell UX-DA003 Dual FDA + NMPA Clearance
Ten years after the first-in-human trial, China is once again setting a milestone. On June 3, 2026, China's NMPA cleared the IND application for UniXell UX-DA003, an iPSC-derived dopaminergic neuron therapy for Parkinson's disease. Twenty days later, on June 23, 2026, the US FDA cleared the same IND — making UX-DA003 one of the first Chinese iPSC-derived therapies to run a coordinated China-US clinical program from day one. (Note: UX-DA003 is technically a stem-cell-derived therapy, but its iPSC platform sits at the intersection of stem cell medicine and gene therapy; the dual clearance is a watershed for both fields.)
For international patients, the dual-track clearance is a quality signal: the same iPSC line, the same differentiation protocol, and the same release testing were accepted by both regulators. Read our full June 25 news article on the UX-DA003 clearance for the announcement, and our stem cell therapy in China pillar guide for the broader cell therapy landscape.
🧬 Active Therapy Areas
Chinese CRISPR and gene therapy trials cluster into four major disease areas. Each card summarizes the modality, current state, and typical patient profile.
🎗️ Cancer (CRISPR-Edited CAR-T, TCR-T, NK)
Modality: Ex vivo CRISPR-edited T cells, NK cells, and TCR-T cells targeting hematologic and solid tumors
Current state: China has 7 NMPA-approved CAR-T products (more than the US), including the world's first CAR-T for a solid tumor (satri-cel for Claudin18.2+ gastric/GEJ adenocarcinoma, approved June 2026). Active CRISPR-edited CAR-T programs for multiple myeloma, lymphoma, leukemia, and solid tumors.
Patient profile: Relapsed/refractory hematologic malignancies, advanced solid tumors with limited standard-care options, including post-CAR-T relapses
Why China: Largest pool of CAR-T-experienced centers, 7 approved products to choose from, 50-70% lower cost than US CAR-T ($89K-170K vs $500K-700K). See CAR-T clinical trials guide.
🩸 Blood Disorders (Beta-Thalassemia, Sickle Cell, Hemophilia)
Modality: Ex vivo CRISPR-edited hematopoietic stem cells (HSCs) or in vivo gene addition
Current state: Multiple active trials for transfusion-dependent beta-thalassemia (TBDT), sickle cell disease, and hemophilia A/B. China's large TBDT patient population (especially in southern provinces) makes it an efficient trial site.
Patient profile: Transfusion-dependent beta-thalassemia, severe hemophilia, sickle cell disease
Why China: Same CRISPR platforms (notably BCL11A editing) as Western trials, with shorter enrollment timelines and lower cost. See bone marrow transplant guide for transplant-context information.
🧬 Inherited Genetic Diseases (Eye, Liver, Neuromuscular)
Modality: In vivo AAV-based gene addition or in vivo CRISPR base editing
Current state: Active trials for inherited retinal dystrophies (RPE65, RPGR), hereditary hearing loss (OTOF), transthyretin amyloidosis, and other rare monogenic disorders. Several programs also target G6PD deficiency and phenylketonuria.
Patient profile: Confirmed genetic diagnosis, often pediatric or young adult patients, few or no approved treatment options
Why China: China's large population means higher absolute numbers of rare disease patients, enabling faster trial enrollment than single-country studies in smaller markets. The Beijing international hospital guide lists the most relevant rare-disease trial sites.
🦠 Infectious Diseases (HIV, HBV, HPV)
Modality: Ex vivo gene-edited immune cells, in vivo CRISPR antivirals, therapeutic vaccines
Current state: Multiple programs in chronic hepatitis B "functional cure" using gene editing to silence cccDNA or integrated HBV DNA; HIV "shock and kill" strategies using CRISPR-edited T cells; and HPV-related cervical intraepithelial neoplasia trials using CRISPR-based therapeutic vaccines.
Patient profile: Chronic HBV with detectable viral load despite nucleoside therapy, HIV-positive patients with controlled viremia, HPV-driven pre-cancerous lesions
Why China: China's HBV patient population is among the largest globally, making it the most efficient setting for HBV cure research.
🏥 Top Hospitals and Research Centers for CRISPR and Gene Therapy
China's CRISPR and gene therapy clinical work is concentrated in a small number of high-volume academic medical centers. The institutions below are where most international patient trial enrollments are routed.
🏥 West China Hospital, Sichuan University
Location: Chengdu
Gene therapy focus: Site of the 2016 first-in-human CRISPR cancer trial; active CRISPR-edited CAR-T, TCR-T, and gene-edited stem cell programs in oncology
Languages: English, dedicated international patient service
🏅 JCI Accredited | National Clinical Key Specialty
🏥 Peking University Cancer Hospital
Location: Beijing
Gene therapy focus: CAR-T, TCR-T, and CRISPR-edited cell therapy trials for solid tumors and hematologic malignancies
Languages: English, dedicated international patient service
🏅 JCI Accredited | National Cancer Center
🏥 Ruijin Hospital, Shanghai Jiao Tong University
Location: Shanghai
Gene therapy focus: CAR-T for hematologic malignancies, beta-thalassemia HSC gene editing, gene therapy for metabolic disease
Languages: English, dedicated international patient service
🏅 JCI Accredited | Shanghai Top-Tier Academic Hospital
🏥 Tongji Hospital, Tongji Medical College (HUST)
Location: Wuhan
Gene therapy focus: Hematologic CAR-T trials, large-volume cellular therapy program, recent 5G-remote-surgery demonstration — see our June 7 news on the Tongji 5G demonstration
Languages: English, dedicated international patient service
🏅 JCI Accredited | National Clinical Key Specialty
🏥 Children's Hospital of Fudan University
Location: Shanghai
Gene therapy focus: Pediatric gene therapy trials — beta-thalassemia, hemophilia, spinal muscular atrophy, inherited retinal disease, rare metabolic disorders
Languages: English, dedicated international patient service
🏅 National Pediatric Clinical Research Center
For broader hospital selection in major cities, see our Beijing hospital guide, Shanghai hospital guide, and Guangzhou hospital guide.
🗺️ International Patient Access: Trial Enrollment and Hospital Programs
For international patients, there are two main pathways into CRISPR and gene therapy in China: (1) enrollment in a registered clinical trial, and (2) treatment with an approved product (where the indication is approved and the patient meets clinical criteria). Below is a typical 5-step access path.
Free Indication Matching
Send your diagnosis, prior treatment history, imaging, and genetic test results (where relevant). We match you to active trials or approved products that fit your indication, eligibility, and goals. Response within 3-5 business days.
Trial Sponsor / Hospital Pre-Screening
The trial sponsor or hospital international office reviews your records against the trial's inclusion/exclusion criteria. If eligible, you receive a trial synopsis, consent form summary, and cost schedule (often $0 for trial-covered patients; otherwise the cost of the cell product, hospital fees, and supportive care).
Visa and Travel Logistics
The hospital issues a medical visa invitation letter. For most nationalities, an M-visa (medical) allows 6-month stays, extendable. Some patients use the Hainan visa-free policy if accessing a Boao Lecheng hospital. See our medical visa guide and how to book a hospital appointment.
Aphesis, Cell Manufacturing, and Treatment
For ex vivo therapies (CAR-T, gene-edited HSCs): cells are collected, manufactured (typically 2-4 weeks for CAR-T), and reinfused. For in vivo gene therapies: a single infusion or injection, often as outpatient. Hospital stay for the first 2-4 weeks is standard for monitoring.
Follow-Up and Outcome Tracking
Trial patients are followed per protocol — often for 2-5 years. Telemedicine follow-up with your Chinese treating team is standard, with local oncologist coordination in your home country. Approved therapy patients are typically followed for life, with structured response assessments.
❓ Frequently Asked Questions
Why does China host the largest number of CRISPR clinical trials?
China's NMPA permits a more streamlined path for gene-editing therapies to enter registered clinical trials than the US FDA or EU EMA. Large hospital networks, large patient populations, and lower per-patient trial costs also make it efficient to run many parallel programs. The combination of regulatory accessibility and clinical capacity produces the world's deepest CRISPR trial pipeline.
What was the first-in-human CRISPR cancer trial?
The first-in-human CRISPR clinical trial was conducted in 2016 at West China Hospital (Sichuan University), in which PD-1 gene-edited autologous T cells were used to treat metastatic non-small cell lung cancer. The trial opened the global era of in-human CRISPR medicine and demonstrated the safety of ex vivo gene editing.
Can an international patient enroll in a CRISPR or gene therapy trial in China?
Yes, in many cases. Many Chinese cancer centers and blood-disease centers accept international patients into registered gene therapy and gene-editing trials, particularly for indications like relapsed B-cell malignancies, beta-thalassemia, hemophilia, and inherited retinal disease. Enrollment requires medical records review, eligibility screening, and informed consent in the trial language (Chinese + translated version).
How much does gene therapy cost in China?
Gene therapy in China typically costs 50-70% less than in the US. Examples: CAR-T therapy in China runs $89K-170K vs $500K-700K in the US; ex vivo gene-edited cell therapies run $80K-200K in China vs $300K-500K+ in the US. For clinical trial enrollment, the cost is often covered by the trial sponsor.
⚠️ Important: Gene therapy and CRISPR clinical trials have strict eligibility criteria. Patients must typically have failed standard-of-care therapy, meet specific disease markers (e.g., confirmed target antigen, specific genetic variant), and be in adequate organ function for the planned treatment. Trial enrollment is at the discretion of the trial sponsor and treating physician.
🎯 Considering Gene Therapy or a CRISPR Trial in China?
Get a free, no-obligation case review. We'll identify active trials and approved products that match your indication, and provide an honest assessment of eligibility and cost.
Start Free Case ReviewLast updated: July 1, 2026 | Information reflects publicly available trial and regulatory data as of publication. Trial enrollment and approval status change frequently; final eligibility confirmed after consultation. This guide is informational and not medical advice.